By Leslie A. Pappas ( August 17, 2022, 4:15 PM EDT) -- Officers and directors of Nektar Therapeutics misled the public about the prospects of the company's cancer-fighting immunotherapy treatment and then sold more than $171 million worth of their stock before the truth sent shares plummeting, a new derivative complaint filed in Delaware Chancery Court alleges....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.